Antiviral agents and uses thereof

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted Patent US12590092B2 to Griffith University for antiviral compounds of Formula (I) and pharmaceutical compositions for treating viral infections. The patent, with 21 allowed claims, names Mark Von Itzstein, Ibrahim El-Deeb, Patrice Guillon, and Larissa Heilig as inventors. Filing date was January 28, 2022.

View original document View source feed page

What changed

Griffith University has received US Patent 12590092B2 for antiviral agents comprising compounds of Formula (I) and their uses in treating viral infections. The patent covers pharmaceutical compositions containing these compounds and methods of treatment. The invention relates to heterocyclic, heteroaryl, cycloalkyl, and aryl ring structures with antiviral properties.

Pharmaceutical companies and drug manufacturers should review this patent to assess potential licensing needs or freedom-to-operate concerns for antiviral drug development programs. This is a routine patent grant notification and does not impose new compliance obligations on regulated entities.

Source document (simplified)

← USPTO Patent Grants

Antiviral agents and uses thereof

Grant US12590092B2 Kind: B2 Mar 31, 2026

Assignee

GRIFFITH UNIVERSITY

Inventors

Mark Von Itzstein, Ibrahim El-Deeb, Patrice Guillon, Larissa Heilig

Abstract

The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
and to pharmaceutical compositions comprising the compound. In Formula (I), R3 is selected from the group consisting of:

wherein rings W, X, Y and Z may relate to various heterocyclic, heteroaryl, cycloalkyl, cycloalkenyl, and/or aryl rings. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection.